| 產品名稱 |
C1R-B7 |
| 商品貨號 |
B164076 |
| Organism |
Homo sapiens, human |
| Cell Type |
B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
mixed; semi-attached |
| Biosafety Level |
2 Cells contain herpesvirus
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
It expresses surface HLA B7 but does not secrete HLA B7. C1R-B7 is a stable transfectant cell line established in 1988 with a normal major histocompatibility complex (MHC) HLA B7 gene. B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy. C1R-B7 may be used as a control for C1R-sB7; in CTL experiments and for producing control supernatants. |
| Derivation |
C1R-B7 is a stable transfectant cell line established in 1988 with a normal major histocompatibility complex (MHC) HLA B7 gene. It expresses surface HLA B7 but does not secrete HLA B7. C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. |
| Antigen Expression |
Expresses surface HLA B7; does not secrete HLA B7 |
| Genes Expressed |
Expresses surface HLA B7; does not secrete HLA B7 |
| Comments |
C1R-B7 is a stable transfectant cell line established in 1988 with a normal major histocompatibility complex (MHC) HLA B7 gene. It expresses surface HLA B7 but does not secrete HLA B7. C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. C1R-B7 may be used as a control for C1R-sB7; in CTL experiments and for producing control supernatants. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Cultures can be maintained by transferring floating cells to additional flasks. Attached cells may be subcultured by scraping. |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| STR Profile |
Amelogenin: X CSF1PO: 6,10 D13S317: 11,13 D16S539: 9,13 D5S818: 10,13 D7S820: 7,12 THO1: 8 TPOX: 8 vWA: 17 |
| Name of Depositor |
F Grumet |
| Year of Origin |
1988 |
| References |
Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
|
